Literature DB >> 29773603

Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.

Yang Y Ding1,2, Julie W Stern1,2, Tracey F Jubelirer1,2, Gerald B Wertheim3, Fumin Lin4, Fengqi Chang4, Zhaohui Gu5, Charles G Mullighan5, Yong Li1, Richard C Harvey6, I-Ming Chen6, Cheryl L Willman6, Stephen P Hunger1,2, Marilyn M Li4, Sarah K Tasian7,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29773603      PMCID: PMC6119161          DOI: 10.3324/haematol.2018.192088

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors:  Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

2.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Authors:  K R Schultz; A Carroll; N A Heerema; W P Bowman; A Aledo; W B Slayton; H Sather; M Devidas; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

3.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

Authors:  Kathryn G Roberts; Zhaohui Gu; Debbie Payne-Turner; Kelly McCastlain; Richard C Harvey; I-Ming Chen; Deqing Pei; Ilaria Iacobucci; Marcus Valentine; Stanley B Pounds; Lei Shi; Yongjin Li; Jinghui Zhang; Cheng Cheng; Alessandro Rambaldi; Manuela Tosi; Orietta Spinelli; Jerald P Radich; Mark D Minden; Jacob M Rowe; Selina Luger; Mark R Litzow; Martin S Tallman; Peter H Wiernik; Ravi Bhatia; Ibrahim Aldoss; Jessica Kohlschmidt; Krzysztof Mrózek; Guido Marcucci; Clara D Bloomfield; Wendy Stock; Stephen Kornblau; Hagop M Kantarjian; Marina Konopleva; Elisabeth Paietta; Cheryl L Willman; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

4.  IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Martin Stanulla; Elif Dagdan; Marketa Zaliova; Anja Möricke; Chiara Palmi; Giovanni Cazzaniga; Cornelia Eckert; Geertruy Te Kronnie; Jean-Pierre Bourquin; Beat Bornhauser; Rolf Koehler; Claus R Bartram; Wolf-Dieter Ludwig; Kirsten Bleckmann; Stefanie Groeneveld-Krentz; Denis Schewe; Stefanie V Junk; Laura Hinze; Norman Klein; Christian P Kratz; Andrea Biondi; Arndt Borkhardt; Andreas Kulozik; Martina U Muckenthaler; Giuseppe Basso; Maria Grazia Valsecchi; Shai Izraeli; Britt-Sabina Petersen; Andre Franke; Petra Dörge; Doris Steinemann; Oskar A Haas; Renate Panzer-Grümayer; Hélène Cavé; Richard S Houlston; Gunnar Cario; Martin Schrappe; Martin Zimmermann
Journal:  J Clin Oncol       Date:  2018-03-02       Impact factor: 44.544

5.  Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; David T Teachey; Yong Li; Feng Shen; Richard C Harvey; I-Ming Chen; Theresa Ryan; Tiffaney L Vincent; Cheryl L Willman; Alexander E Perl; Stephen P Hunger; Mignon L Loh; Martin Carroll; Stephan A Grupp
Journal:  Blood       Date:  2016-10-24       Impact factor: 22.113

6.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.

Authors:  Michael A Pulsipher; Chris Carlson; Bryan Langholz; Donna A Wall; Kirk R Schultz; Nancy Bunin; Ilan Kirsch; Julie M Gastier-Foster; Michael Borowitz; Cindy Desmarais; David Williamson; Michael Kalos; Stephan A Grupp
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

7.  Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Yongjin Li; Kathryn G Roberts; Stephanie M Dobson; Jaeseung C Kim; Debbie Payne-Turner; Richard C Harvey; Marcus Valentine; Kelly McCastlain; John Easton; Donald Yergeau; Laura J Janke; Ying Shao; I-Ming L Chen; Michael Rusch; Sasan Zandi; Steven M Kornblau; Marina Konopleva; Elias Jabbour; Elisabeth M Paietta; Jacob M Rowe; Ching-Hon Pui; Julie Gastier-Foster; Zhaohui Gu; Shalini Reshmi; Mignon L Loh; Janis Racevskis; Martin S Tallman; Peter H Wiernik; Mark R Litzow; Cheryl L Willman; John D McPherson; James R Downing; Jinghui Zhang; John E Dick; Stephen P Hunger; Charles G Mullighan
Journal:  Cancer Cell       Date:  2016-02-08       Impact factor: 31.743

8.  Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

Authors:  Peter Bader; Hermann Kreyenberg; Günter H R Henze; Cornelia Eckert; Miriam Reising; Andre Willasch; Andrea Barth; Arndt Borkhardt; Christina Peters; Rupert Handgretinger; Karl-Walter Sykora; Wolfgang Holter; Hartmut Kabisch; Thomas Klingebiel; Arend von Stackelberg
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

9.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

10.  EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.

Authors:  Claire Schwab; Sarra L Ryan; Lucy Chilton; Alannah Elliott; James Murray; Stacey Richardson; Christopher Wragg; John Moppett; Michelle Cummins; Oliver Tunstall; Catriona A Parker; Vaskar Saha; Nicholas Goulden; Ajay Vora; Anthony V Moorman; Christine J Harrison
Journal:  Blood       Date:  2016-02-12       Impact factor: 22.113

View more
  16 in total

Review 1.  Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Sarah K Tasian
Journal:  Blood Adv       Date:  2020-01-14

2.  Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.

Authors:  Fengqi Chang; Fumin Lin; Kajia Cao; Lea F Surrey; Richard Aplenc; Rochelle Bagatell; Adam C Resnick; Mariarita Santi; Phillip B Storm; Sarah K Tasian; Angela J Waanders; Stephen P Hunger; Marilyn M Li
Journal:  J Mol Diagn       Date:  2019-06-27       Impact factor: 5.568

Review 3.  Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?

Authors:  Thai Hoa Tran; Sarah K Tasian
Journal:  Best Pract Res Clin Haematol       Date:  2021-10-23       Impact factor: 3.020

4.  Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.

Authors:  Hiroaki Goto; Yuki Yoshino; Mieko Ito; Junichi Nagai; Tadashi Kumamoto; Takesi Inukai; Yukari Sakurai; Naoyuki Miyagawa; Dai Keino; Tomoko Yokosuka; Fuminori Iwasaki; Satoshi Hamanoue; Masae Shiomi; Shoko Goto
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-06       Impact factor: 3.333

5.  Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.

Authors:  Rimvydas Norvilas; Vaidas Dirse; Ruta Semaskeviciene; Orinta Mickeviciute; Egle Gineikiene; Mindaugas Stoskus; Goda Vaitkeviciene; Jelena Rascon; Laimonas Griskevicius
Journal:  BMC Cancer       Date:  2021-03-29       Impact factor: 4.430

Review 6.  Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.

Authors:  Alexander Gavralidis; Andrew M Brunner
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

7.  Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.

Authors:  Yunchao Chang; Jaeki Min; Jamie A Jarusiewicz; Marisa Actis; Shanshan Yu-Chen Bradford; Anand Mayasundari; Lei Yang; Divyabharathi Chepyala; Lisa J Alcock; Kathryn G Roberts; Stanley Nithianantham; Dylan Maxwell; Lauren Rowland; Randolph Larsen; Aman Seth; Hiroaki Goto; Toshihiko Imamura; Koshi Akahane; Baranda S Hansen; Shondra M Pruett-Miller; Elisabeth M Paietta; Mark R Litzow; Chunxu Qu; Jun J Yang; Marcus Fischer; Zoran Rankovic; Charles G Mullighan
Journal:  Blood       Date:  2021-12-09       Impact factor: 25.476

8.  Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.

Authors:  Sarah K Tasian; Kai Tan; Yang-Yang Ding; Hannah Kim; Kellyn Madden; Joseph P Loftus; Gregory M Chen; David Hottman Allen; Ruitao Zhang; Jason Xu; Chia-Hui Chen; Yuxuan Hu
Journal:  Clin Cancer Res       Date:  2021-07-01       Impact factor: 12.531

Review 9.  Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Kathryn G Roberts
Journal:  Genes (Basel)       Date:  2021-05-01       Impact factor: 4.096

10.  High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Authors:  Jae Wook Lee; Yonggoo Kim; Bin Cho; Seongkoo Kim; Pil-Sang Jang; Jaewoong Lee; Hanwool Cho; Gun Dong Lee; Nack-Gyun Chung; Myungshin Kim
Journal:  Cancer Med       Date:  2020-05-07       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.